Clinical Trials

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

EudraCT / EU CT No
2024-515279-37-00
Protocol No
CA088-1007

Trial information

Medical condition
Relapsed or refractory, lenalidomide-exposed multiple myeloma
Trial phase
Phase 3
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Start date
12/03/2025
End date
Recruiting
Main objective
Compare efficacy and safety of arlocabtagene autoleucel (BMS-986393), a GPRC5D-directed CAR-T therapy, with standard regimens.

Locations and Contact points